Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy

Introduction The purpose of this retrospective study was to investigate the prognostic impact of neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), derived NLR (dNLR) and systemic immune‐inflammation index (SII) in predicting outcomes for patients with locally advanced non‐sma...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical imaging and radiation oncology 2022-02, Vol.66 (1), p.146-157
Main Authors: Delikgoz Soykut, Ela, Kemal, Yasemin, Karacin, Cengiz, Karaoglanoglu, Ozden, Kurt, Mumin, Aytac Arslan, Suheyla
Format: Article
Language:English
Subjects:
Biomarkers
Carcinoma, Non-Small-Cell Lung - radiotherapy
Chemoradiotherapy
Chemotherapy
Humans
immune inflammation biomarkers
Inflammation
Lung cancer
Lung Neoplasms - radiotherapy
Lymphocytes
Medical prognosis
Neutrophils
non‐small‐cell lung cancer
Prognosis
prognostic factor
Radiation therapy
Radiation Tolerance
radiosensitivity
radiotherapy
Retrospective Studies
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The purpose of this retrospective study was to investigate the prognostic impact of neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), derived NLR (dNLR) and systemic immune‐inflammation index (SII) in predicting outcomes for patients with locally advanced non‐small‐cell lung cancer (NSCLC). The secondary endpoint was to evaluate the radiosensitivity in terms of response rate. Methods Newly diagnosed locally advanced NSCLC patients were enrolled. Immune inflammation biomarkers were calculated from baseline blood samples. Patients were stratified in two groups based on optimal cut‐off values for each biomarker. The associations between biomarkers and overall survival (OS), progression‐free survival (PFS), local regional recurrence‐free survival (LRRFS), and also response to radiotherapy were analysed. Results A total of 392 patients were included. Five‐year OS, PFS and LRRFS rates were 14.6%, 12.1%, and 13.4% respectively. Optimal cut‐off values for NLR, PLR, dNLR and SII were 3.07, 166, 2.02 and 817 respectively. Low NLR (HR 1.73, 95% CI 1.34–2.24, P 
ISSN:1754-9477
1754-9485
DOI:10.1111/1754-9485.13341